PT1307264E - Nova composicao farmaceutica - Google Patents

Nova composicao farmaceutica

Info

Publication number
PT1307264E
PT1307264E PT01969439T PT01969439T PT1307264E PT 1307264 E PT1307264 E PT 1307264E PT 01969439 T PT01969439 T PT 01969439T PT 01969439 T PT01969439 T PT 01969439T PT 1307264 E PT1307264 E PT 1307264E
Authority
PT
Portugal
Prior art keywords
pharmaceutical composition
new pharmaceutical
new
composition
pharmaceutical
Prior art date
Application number
PT01969439T
Other languages
English (en)
Inventor
Pierre Barbier
Paul Hadvary
Hans Lengsfeld
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8169384&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1307264(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PT1307264E publication Critical patent/PT1307264E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
PT01969439T 2000-07-28 2001-07-19 Nova composicao farmaceutica PT1307264E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00116393 2000-07-28
PCT/EP2001/008363 WO2002009815A2 (en) 2000-07-28 2001-07-19 New pharmaceutical composition

Publications (1)

Publication Number Publication Date
PT1307264E true PT1307264E (pt) 2005-02-28

Family

ID=8169384

Family Applications (1)

Application Number Title Priority Date Filing Date
PT01969439T PT1307264E (pt) 2000-07-28 2001-07-19 Nova composicao farmaceutica

Country Status (38)

Country Link
US (5) US6756364B2 (pt)
EP (1) EP1307264B1 (pt)
JP (2) JP4265911B2 (pt)
KR (1) KR100572785B1 (pt)
CN (1) CN100423715C (pt)
AR (1) AR033548A1 (pt)
AT (1) ATE279961T1 (pt)
AU (2) AU8969901A (pt)
BR (1) BR0112799B1 (pt)
CA (1) CA2416901C (pt)
CZ (1) CZ302087B6 (pt)
DE (1) DE60106623T2 (pt)
EC (1) ECSP034450A (pt)
EG (1) EG24357A (pt)
ES (1) ES2230362T3 (pt)
GT (1) GT200100152A (pt)
HK (1) HK1058636A1 (pt)
HR (1) HRP20030029B1 (pt)
HU (1) HU229292B1 (pt)
IL (2) IL154008A0 (pt)
JO (1) JO2320B1 (pt)
MA (1) MA26937A1 (pt)
ME (1) MEP90508A (pt)
MX (1) MXPA03000771A (pt)
MY (1) MY127247A (pt)
NO (1) NO330546B1 (pt)
NZ (1) NZ523684A (pt)
PA (1) PA8523201A1 (pt)
PE (1) PE20020336A1 (pt)
PL (1) PL204443B1 (pt)
PT (1) PT1307264E (pt)
RS (1) RS50397B (pt)
RU (1) RU2241462C2 (pt)
SI (1) SI1307264T1 (pt)
TW (1) TWI275395B (pt)
UY (1) UY26860A1 (pt)
WO (1) WO2002009815A2 (pt)
ZA (1) ZA200300456B (pt)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2240516T3 (es) * 2000-07-28 2005-10-16 F. Hoffmann-La Roche Ag Nuevo uso de los inhibidores de lipasa.
PL204443B1 (pl) * 2000-07-28 2010-01-29 Hoffmann La Roche Kompozycja farmaceutyczna zawierająca inhibitor lipazy, sposób wytwarzania kompozycji farmaceutycznej, zestaw do leczenia otyłości, zastosowanie kompozycji farmaceutycznej oraz zastosowanie orlistatu i substancji wiążącej kwasy żółciowe
US7033373B2 (en) 2000-11-03 2006-04-25 Satiety, Inc. Method and device for use in minimally invasive placement of space-occupying intragastric devices
US6558400B2 (en) 2001-05-30 2003-05-06 Satiety, Inc. Obesity treatment tools and methods
WO2003090742A1 (en) * 2002-04-26 2003-11-06 F. Hoffmann-La Roche Ag Pharmaceutical composition comprising a lipase inhibitor and glucomannan
US6746460B2 (en) 2002-08-07 2004-06-08 Satiety, Inc. Intra-gastric fastening devices
US7033384B2 (en) 2002-08-30 2006-04-25 Satiety, Inc. Stented anchoring of gastric space-occupying devices
US7214233B2 (en) 2002-08-30 2007-05-08 Satiety, Inc. Methods and devices for maintaining a space occupying device in a relatively fixed location within a stomach
DE60304723T2 (de) * 2002-09-09 2007-04-05 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno VERZWEIGTE ALPHA-GLUCANE FüR DAS GEWICHTSMANAGEMENT
US7220237B2 (en) 2002-10-23 2007-05-22 Satiety, Inc. Method and device for use in endoscopic organ procedures
DK2368553T3 (en) 2003-04-08 2015-02-09 Progenics Pharm Inc Pharmaceutical preparation comprising methylnaltrexone
US7175638B2 (en) 2003-04-16 2007-02-13 Satiety, Inc. Method and devices for modifying the function of a body organ
US7914543B2 (en) 2003-10-14 2011-03-29 Satiety, Inc. Single fold device for tissue fixation
US7097650B2 (en) * 2003-10-14 2006-08-29 Satiety, Inc. System for tissue approximation and fixation
US7648625B2 (en) * 2003-12-19 2010-01-19 Shell Oil Company Systems, methods, and catalysts for producing a crude product
US20050177176A1 (en) 2004-02-05 2005-08-11 Craig Gerbi Single-fold system for tissue approximation and fixation
EP1713402B1 (en) 2004-02-13 2018-07-04 Ethicon Endo-Surgery, Inc. Device for reducing stomach volume
WO2006004574A2 (en) * 2004-02-19 2006-01-12 Abbott Laboratories Method for using gamma cyclodextrin to control blood glucose and insulin secretion
CA2557722C (en) 2004-02-27 2013-02-12 Satiety, Inc. Methods and devices for reducing hollow organ volume
US8252009B2 (en) 2004-03-09 2012-08-28 Ethicon Endo-Surgery, Inc. Devices and methods for placement of partitions within a hollow body organ
US9028511B2 (en) 2004-03-09 2015-05-12 Ethicon Endo-Surgery, Inc. Devices and methods for placement of partitions within a hollow body organ
US8628547B2 (en) 2004-03-09 2014-01-14 Ethicon Endo-Surgery, Inc. Devices and methods for placement of partitions within a hollow body organ
US8449560B2 (en) 2004-03-09 2013-05-28 Satiety, Inc. Devices and methods for placement of partitions within a hollow body organ
CA2561193A1 (en) 2004-03-26 2005-10-20 Satiety, Inc. Systems and methods for treating obesity
US20050276781A1 (en) * 2004-06-09 2005-12-15 Ross Edward A Molecularly imprinted phosphate binders for therapeutic use
WO2006035296A1 (en) * 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Process for the preparation of an orlistat derivative useful as reference standard in the determination of the purity of orlistat and process for the preparation of orlistat
US20060106288A1 (en) 2004-11-17 2006-05-18 Roth Alex T Remote tissue retraction device
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
CN101171010B (zh) * 2005-03-07 2014-09-17 芝加哥大学 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
US20090208584A1 (en) * 2005-06-09 2009-08-20 Tomohiro Yoshinari Solid preparation
CA2610922A1 (en) * 2005-06-13 2006-12-21 Yeda Research And Development Co. Ltd. Use of allylmercaptocaptopril for treating or preventing obesity and obesity related diseases
AR056499A1 (es) * 2005-09-06 2007-10-10 Serapis Farmaceuticals Ltd Compuestos
JP2009514966A (ja) * 2005-11-08 2009-04-09 ジェンザイム・コーポレーション 高リン血症のためのマグネシウム含有重合体
CA2647325C (en) * 2005-12-12 2015-03-24 Allaccem, Inc. Methods and systems for preparing antimicrobial bridged polycyclic compounds
EP1803714A1 (en) * 2005-12-27 2007-07-04 KRKA, tovarna zdravil, d.d., Novo mesto Process for preparing crystalline forms of orlistat
WO2007086054A2 (en) * 2006-01-25 2007-08-02 Yeda Research And Development Co. Ltd. A process for preparing allylmercaptocaptopril (cpssa) and related asymmetrical disulfides
WO2007094779A1 (en) * 2006-02-14 2007-08-23 Teva Pharmaceutical Industries Ltd. Pharmaceutical formulations of aliphatic amine polymers and methods for their manufacture
DE602006004695D1 (de) * 2006-02-14 2009-02-26 Teva Pharma Pharmazeutische Zubereitungsform von aliphatischen amin-Polymeren und Verfahren zu deren Herstellung
US7964182B2 (en) * 2006-09-01 2011-06-21 USV, Ltd Pharmaceutical compositions comprising phosphate-binding polymer
CA2749074A1 (en) * 2006-09-01 2008-05-29 Usv Limited Process for the preparation of sevelamer hydrochloride and formulation thereof
US7662373B2 (en) * 2006-09-18 2010-02-16 Thompson Ronald J Method and composition of a medicament to decrease the adverse events of Olistat, an oral lipase inhibitor
US20080069906A1 (en) * 2006-09-18 2008-03-20 Thompson Ronald J Method and composition of a carminative herb or natural supplement to decrease the adverse effects of orlistat, and oral lipase inhibitor
GB0618725D0 (en) * 2006-09-23 2006-11-01 Jagotec Ag Composition containing inhibitors of gastro-intestinal lipase
WO2008070308A2 (en) * 2006-10-24 2008-06-12 Thompson Md Ronald J Method and composition of a carminative herb or natural supplement to decrease the adverse effects of orlistat, an oral lipase inhibitor, and a method with formulations to concurrently reduce fracture risk and insure appropriate fatsoluble vitamin supplementation when using orlistat, an oral lipase inhibitor, and a method o
PT2124884T (pt) * 2006-12-22 2019-09-17 Ironwood Pharmaceuticals Inc Composições compreendendo sequestradores de ácido biliar para tratar distúrbios esofágicos
EP1944025A1 (en) * 2007-01-09 2008-07-16 Ranbaxy Laboratories Limited Stable pharmaceutical compositions of orlistat
NZ579785A (en) 2007-02-21 2012-06-29 Allaccem Inc Bridged polycyclic compound based compositions for the inhibition and amelioration of disease
PT2139890E (pt) 2007-03-29 2014-09-03 Wyeth Llc Antagonistas do receptor opióide periférico e respectivas utilizações
EP2134718A2 (en) 2007-03-29 2009-12-23 Progenics Pharmaceuticals, Inc. Crystal forms of (r)-n-methylnaltrexone bromide and uses thereof
PL2137191T3 (pl) 2007-03-29 2016-12-30 Antagoniści obwodowego receptora opioidowego i ich zastosowania
US20090023682A1 (en) * 2007-07-19 2009-01-22 Joseph Artiss Composition Comprising Dietary Fat Complexer and Methods of Using Same
US8153618B2 (en) * 2007-08-10 2012-04-10 Allaccem, Inc. Bridged polycyclic compound based compositions for topical applications for pets
US8188068B2 (en) * 2007-08-10 2012-05-29 Allaccem, Inc. Bridged polycyclic compound based compositions for coating oral surfaces in pets
US8153617B2 (en) * 2007-08-10 2012-04-10 Allaccem, Inc. Bridged polycyclic compound based compositions for coating oral surfaces in humans
US20090074833A1 (en) * 2007-08-17 2009-03-19 Whiteford Jeffery A Bridged polycyclic compound based compositions for controlling bone resorption
MX2010004072A (es) * 2007-10-15 2010-09-14 Inventis Dds Pvt Ltd Composicion farmaceutica de orlistat.
AU2008349873B2 (en) 2008-02-06 2014-02-13 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone
PL216542B1 (pl) 2008-03-20 2014-04-30 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku
AU2009225434B2 (en) 2008-03-21 2014-05-22 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
US20100004218A1 (en) * 2008-06-20 2010-01-07 Whiteford Jeffery A Bridged polycyclic compound based compositions for renal therapy
US20100016270A1 (en) * 2008-06-20 2010-01-21 Whiteford Jeffery A Bridged polycyclic compound based compositions for controlling cholesterol levels
CA2735962A1 (en) * 2008-09-02 2010-04-15 Usv Limited Crosslinked polymers
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
US9339480B2 (en) * 2008-11-26 2016-05-17 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of obesity and diabetes
GB0900350D0 (en) * 2009-01-09 2009-02-11 Cambridge Entpr Ltd Formulations of viable bacteria for oral delivery
WO2010093243A1 (en) 2009-02-12 2010-08-19 Coöperatieve Mirzorg U.A., Arnhem Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders
US20100330175A1 (en) * 2009-06-24 2010-12-30 Jobdevairakkam Christopher N Cross-linked polyallylamine tablet core
US20110152204A1 (en) * 2009-12-18 2011-06-23 Satiogen Pharmaceuticals, Inc. Treatment of Obesity or Diabetes with Bile Acid Sequestrants
WO2011150286A2 (en) 2010-05-26 2011-12-01 Satiogen Pharmaceuticals,Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
RS60901B1 (sr) 2010-11-08 2020-11-30 Albireo Ab Ibat inhibitori za lečenje oboljenja jetre
US11154559B2 (en) 2011-09-29 2021-10-26 Ethicon Endo-Surgery, Inc. Methods and compositions of bile acids
CN104023727B (zh) 2011-10-28 2017-04-05 鲁美纳医药公司 用于治疗小儿胆汁淤积性肝病的胆汁酸再循环抑制剂
EP2591768B1 (en) * 2011-11-14 2014-07-16 Deva Holding Anonim Sirketi Single unit dosage formulations of sevelamer and fat soluble vitamins and surface active agents
JP2013147488A (ja) * 2011-12-21 2013-08-01 Taisho Pharmaceutical Co Ltd 固形製剤
GB201122213D0 (en) * 2011-12-23 2012-02-01 Norgine Bv Compositions
US8252312B1 (en) * 2011-12-27 2012-08-28 David Wong Oral solid composition comprising a lipid absorption inhibitor
LT2916852T (lt) 2012-11-06 2021-06-25 Sigrid Therapeutics Ab Poringa silicio dioksido medžiaga, skirta panaudoti kaip farmacinė arba arba dietinė aktyvi sudedamoji dalis
ES2643057T3 (es) 2012-12-21 2017-11-21 National Health Research Institutes Nanopartículas mesóporas de sílice para la absorción de aceite
RU2552926C1 (ru) * 2014-06-23 2015-06-10 Общество с ограниченной ответственностью "ПРОМОМЕД" Фармацевтическая комбинация для лечения и/или предупреждения нарушений, связанных с избыточным весом и/или ожирением, и способ лечения на ее основе
CA2952406A1 (en) 2014-06-25 2015-12-30 Ea Pharma Co., Ltd. Solid formulation and method for preventing or reducing coloration thereof
US10743813B2 (en) 2014-09-11 2020-08-18 Rattan Nath Diabetes control using postprandial feedback
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
WO2017138876A1 (en) * 2016-02-09 2017-08-17 Albireo Ab Cholestyramine pellets and methods for preparation thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
CA3071285A1 (en) 2017-08-09 2019-02-14 Albireo Ab Cholestyramine granules, oral cholestyramine formulations and use thereof
US11389545B2 (en) * 2018-01-09 2022-07-19 Aqua Regenerative Therapies Llc Bioactive nanoparticles and methods for making same
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CA3100691A1 (en) 2018-06-20 2019-12-26 Albireo Ab Crystal modifications of odevixibat
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
CN108685848B (zh) * 2018-08-13 2020-09-01 中山万汉制药有限公司 一种奥利司他口服乳剂及其制备方法
NL2022615B1 (en) 2019-02-21 2020-08-31 Patrick Alexander Unger Pharmaceutical composition comprising tetrahydrocannabivarin for the prevention and treatment of overweight
CN111297826B (zh) * 2020-04-20 2021-08-03 鲁南制药集团股份有限公司 一种稳定的奥利司他胶囊及其制备方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3692895A (en) * 1970-09-08 1972-09-19 Norman A Nelson Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria
IT1052819B (it) * 1975-12-12 1981-07-20 Fargal Pharmasint Lab Biochim Preparato inibitore dell assorbimento dei lipidi a base di dietilamminoetildestrano
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
DE3414609C1 (de) * 1984-04-18 1985-06-20 Daimler-Benz Ag, 7000 Stuttgart Vorrichtung zur Beeinflussung eines Kuehlluftstromes
IT1190349B (it) * 1986-06-16 1988-02-16 Prodotti Formenti Srl Composizioni farmaceutiche ad attivita' sequestrante degli acidi biliari contenenti colestiramina quale principio attivo,e procedimento per prepararle
US5063210A (en) 1989-04-20 1991-11-05 Lange Iii Louis G Use of sulfated polysaccharides to decrease cholesterol and fatty acid absorption
US5344453A (en) * 1991-05-30 1994-09-06 Boston Medical Products, Inc. Thyroplasty implant
US5616570A (en) * 1991-10-18 1997-04-01 Lange, Iii; Louis G. Use of non-absorbable synthetic sulfated polysaccharides to decrease cholesterol absorbtion
CA2098167C (en) * 1992-06-24 2006-12-19 Dorothea Isler Foodstuffs and feedstuffs containing a lipase inhibitor
US5607669A (en) * 1994-06-10 1997-03-04 Geltex Pharmaceuticals, Inc. Amine polymer sequestrant and method of cholesterol depletion
CA2128044C (en) * 1993-08-05 2007-02-20 Klaus-Dieter Bremer Pharmaceutical compositions comprising a glucosidase and/or amylase inhibitor, and a lipase inhibitor
US5667775A (en) * 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5569452A (en) * 1993-08-31 1996-10-29 Tsrl, Inc. Pharmaceutical formulation having enhanced bile acid binding affinity
TW474813B (en) * 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
US5545414A (en) * 1995-03-22 1996-08-13 Abbott Laboratories Cholesterol lowering food product
JP3832871B2 (ja) * 1995-04-03 2006-10-11 日本製粉株式会社 リパーゼ阻害剤
US6294190B1 (en) 1995-12-26 2001-09-25 Suntory Limited Antiobestic agent containing procyanidin as the active ingredient
US5612026A (en) * 1996-01-25 1997-03-18 The Procter & Gamble Company Cholesterol lowering drink mix compositons
US5883109A (en) * 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
JP3807464B2 (ja) 1997-11-17 2006-08-09 康二 嘉島 肥満防止剤
GB9727131D0 (en) 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
BR9907234A (pt) 1998-01-09 2000-10-10 Geltex Pharma Inc Polìmeros ligantes de gordura
FI113356B (fi) 1998-05-20 2004-04-15 Upm Kymmene Corp Pakkauksenmuodostuslaite
ATE263558T1 (de) * 1998-08-14 2004-04-15 Hoffmann La Roche Lipasehemmer und chitosan enthaltende pharmazeutische zusammensetzungen
JP3774118B2 (ja) * 1998-08-14 2006-05-10 エフ．ホフマン−ラ ロシュ アーゲー リパーゼ阻害剤を含む製薬学的組成物
JP2002524410A (ja) 1998-09-08 2002-08-06 スミスクライン・ビーチャム・コーポレイション リプスタチン誘導体−可溶性繊維錠剤
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
EP1143999B1 (en) 1999-01-22 2004-07-21 Hunza di Pistolesi Elvira & C. S.a.S. Lipoprotein complexes and compositions containing them
AR025609A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
AR025587A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
PL204443B1 (pl) * 2000-07-28 2010-01-29 Hoffmann La Roche Kompozycja farmaceutyczna zawierająca inhibitor lipazy, sposób wytwarzania kompozycji farmaceutycznej, zestaw do leczenia otyłości, zastosowanie kompozycji farmaceutycznej oraz zastosowanie orlistatu i substancji wiążącej kwasy żółciowe

Also Published As

Publication number Publication date
BR0112799B1 (pt) 2017-10-24
ES2230362T3 (es) 2005-05-01
US20040105838A1 (en) 2004-06-03
AU8969901A (en) 2002-02-13
UY26860A1 (es) 2002-01-31
TWI275395B (en) 2007-03-11
PE20020336A1 (es) 2002-05-08
ME00671B (me) 2011-12-20
EP1307264A2 (en) 2003-05-07
US8071571B2 (en) 2011-12-06
ECSP034450A (es) 2003-03-10
PA8523201A1 (es) 2002-10-24
DE60106623T2 (de) 2006-02-02
SI1307264T1 (en) 2005-02-28
US20050136030A1 (en) 2005-06-23
AU2001289699B2 (en) 2006-06-01
IL154008A (en) 2011-12-29
HRP20030029A2 (en) 2004-02-29
CN1444495A (zh) 2003-09-24
JP4265911B2 (ja) 2009-05-20
JO2320B1 (en) 2005-09-12
CA2416901A1 (en) 2002-02-07
MXPA03000771A (es) 2003-06-04
HK1058636A1 (en) 2004-05-28
NO20030418L (no) 2003-01-27
HUP0301281A3 (en) 2005-05-30
CZ2003582A3 (cs) 2004-02-18
BR0112799A (pt) 2003-07-01
AR033548A1 (es) 2003-12-26
YU5003A (sh) 2006-01-16
NO330546B1 (no) 2011-05-16
US6756364B2 (en) 2004-06-29
HRP20030029B1 (en) 2005-06-30
NZ523684A (en) 2005-04-29
GT200100152A (es) 2002-05-16
IL154008A0 (en) 2003-07-31
HUP0301281A2 (hu) 2003-08-28
ATE279961T1 (de) 2004-11-15
MY127247A (en) 2006-11-30
JP2009073833A (ja) 2009-04-09
ZA200300456B (en) 2004-04-16
RS50397B (sr) 2009-12-31
KR20030029796A (ko) 2003-04-16
EP1307264B1 (en) 2004-10-20
US20100203032A1 (en) 2010-08-12
JP2004505067A (ja) 2004-02-19
US20020035089A1 (en) 2002-03-21
DE60106623D1 (de) 2004-11-25
MEP90508A (en) 2011-12-20
HU229292B1 (en) 2013-10-28
US20060269510A1 (en) 2006-11-30
CZ302087B6 (cs) 2010-10-06
EG24357A (en) 2009-03-04
RU2241462C2 (ru) 2004-12-10
NO20030418D0 (no) 2003-01-27
PL204443B1 (pl) 2010-01-29
WO2002009815A2 (en) 2002-02-07
WO2002009815A3 (en) 2002-04-18
KR100572785B1 (ko) 2006-04-19
CN100423715C (zh) 2008-10-08
MA26937A1 (fr) 2004-12-20
CA2416901C (en) 2007-07-03
PL366105A1 (en) 2005-01-24

Similar Documents

Publication Publication Date Title
PT1307264E (pt) Nova composicao farmaceutica
DK1524266T3 (da) Farmaceutisk sammensætning
NO20025450L (no) Ny farmasöytisk sammensetning
IS2932B (is) Fúlvestrant samsetning
FI20105657A (fi) Farmaseuttisia koostumuksia
AR028204A1 (es) Composiciones farmaceuticas electrohiladas
IS6686A (is) Hýdrógel-drifið lyfjaskömmtunarform
ITMI20010748A0 (it) Composizioni farmaceutiche
DE60106275T8 (de) Dermatologische zusammensetzung
FI991485A (fi) Uusi farmaseuttinen koostumus
NO20015175L (no) Farmasöytisk sammensetning
FI20011478A (fi) Farmaseuttinen koostumus
ATE330937T1 (de) Glyburid-zusammensetzung
NO20026123L (no) Farmasöytiske sammensetninger
FI20022128A0 (fi) Farmaseuttinen koostumus
DE60116858D1 (de) Zusammensetzung
ITMI20011637A0 (it) Composizione farmaceutica contenente citalopram
NO20031095L (no) Farmasoytiske sammensetninger
FI4488U1 (fi) Farmaseuttinen koostumus
DE60107312D1 (de) Feste Zusammensetzung
EE200200689A (et) Ravimkoostised
SE0000798D0 (sv) New composition
SE0002779D0 (sv) New composition
DK200100203U4 (da) Farmaceutisk komposition indeholdende citalopram
IDP000026013A (id) Komposisi biolakto-aktif